| Symbol | Company | Owner | Relationship | Date | Transaction | Cost | # Shares | Value ($) | Total Shares | Filing | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| OREXQ | Orexigen Therapeutics, Inc. | BAUPOST GROUP LLC/MA | 10% Owner | Oct 29, 2018 | Sale | $0.01000 | 650,000 | 6,500 | 896,339 | Oct 31, 2018, 04:04 PM | |
| OREXQ | Orexigen Therapeutics, Inc. | KLARMAN SETH A | 10% Owner | Oct 31, 2018 | Sale | $0.01000 | 896,339 | 8,963 | 0 | Oct 31, 2018, 04:04 PM | |
| OREXQ | Orexigen Therapeutics, Inc. | KLARMAN SETH A | 10% Owner | Oct 24, 2018 | Sale | $0.01000 | 28,000 | 280 | 2,198,839 | Oct 26, 2018, 04:12 PM | |
| OREXQ | Orexigen Therapeutics, Inc. | Baupost Group GP, L.L.C. | 10% Owner | Oct 25, 2018 | Sale | $0.01000 | 652,500 | 6,525 | 1,546,339 | Oct 26, 2018, 04:12 PM | |
| OREX | Orexigen Therapeutics, Inc. | Moglia Stephen A. | VP & Chief Accounting Officer | Mar 15, 2018 | Sale | $0.24 | 1,694 | 407 | 0 | Mar 16, 2018, 04:20 PM | |
| OREX | Orexigen Therapeutics, Inc. | NARACHI MICHAEL | CEO & President | May 31, 2017 | Option Exercise | $1.55 | 626 | 970 | 8,356 | Jun 02, 2017, 04:55 PM | |
| OREX | Orexigen Therapeutics, Inc. | Lynch Thomas P. | EVP. General Counsel & Sec. | May 31, 2017 | Option Exercise | $1.55 | 1,704 | 2,641 | 1,704 | Jun 02, 2017, 04:47 PM | |
| OREX | Orexigen Therapeutics, Inc. | Keyes Jason A | SVP, Chief Financial Officer | May 31, 2017 | Option Exercise | $1.55 | 557 | 863 | 3,031 | Jun 02, 2017, 04:44 PM | |
| OREX | Orexigen Therapeutics, Inc. | Cannell Thomas R | EVP, COO, Pres Global Com Prod | May 31, 2017 | Option Exercise | $1.55 | 2,119 | 3,284 | 3,882 | Jun 02, 2017, 04:33 PM | |
| OREX | Orexigen Therapeutics, Inc. | Moglia Stephen A. | VP, Chief Accounting Officer | Dec 19, 2016 | Sale | $1.96 | 800 | 1,568 | 0 | Dec 21, 2016, 12:11 PM | |
| OREX | Orexigen Therapeutics, Inc. | NARACHI MICHAEL | CEO & President | Nov 30, 2016 | Option Exercise | $1.67 | 802 | 1,339 | 6,312 | Dec 02, 2016, 05:11 PM | |
| OREX | Orexigen Therapeutics, Inc. | Keyes Jason A | SVP, Chief Financial Officer | Nov 30, 2016 | Option Exercise | $1.67 | 291 | 486 | 2,474 | Dec 02, 2016, 05:10 PM | |
| OREX | Orexigen Therapeutics, Inc. | Cannell Thomas R | EVP, COO, Pres Global Com Prod | Nov 30, 2016 | Option Exercise | $1.67 | 291 | 486 | 1,763 | Dec 02, 2016, 05:09 PM | |
| OREX | Orexigen Therapeutics, Inc. | NARACHI MICHAEL | CEO & President | May 31, 2016 | Option Exercise | $0.34 | 8,777 | 2,984 | 69,285 | Jun 02, 2016, 11:23 AM | |
| OREX | Orexigen Therapeutics, Inc. | Cannell Thomas R | EVP, Chief Commercial Officer | May 31, 2016 | Option Exercise | $0.34 | 9,632 | 3,275 | 14,723 | Jun 02, 2016, 11:22 AM | |
| OREX | Orexigen Therapeutics, Inc. | Klassen Preston | EVP, Global Development | May 30, 2015 | Option Exercise | $4.17 | 1,860 | 7,756 | 5,990 | Feb 04, 2016, 12:06 PM | |
| OREX | Orexigen Therapeutics, Inc. | Klassen Preston | EVP, Global Development | Nov 30, 2015 | Option Exercise | $2.03 | 4,170 | 8,465 | 10,160 | Feb 04, 2016, 12:06 PM | |
| OREX | Orexigen Therapeutics, Inc. | Cannell Thomas R | EVP, Chief Commercial Officer | Nov 30, 2015 | Option Exercise | $2.03 | 5,091 | 10,335 | 5,091 | Feb 04, 2016, 12:06 PM | |
| OREX | Orexigen Therapeutics, Inc. | NARACHI MICHAEL | CEO & President | May 29, 2015 | Option Exercise | $4.17 | 721 | 3,007 | 58,747 | Feb 04, 2016, 12:04 PM | |
| OREX | Orexigen Therapeutics, Inc. | NARACHI MICHAEL | CEO & President | Nov 30, 2015 | Option Exercise | $2.03 | 1,761 | 3,575 | 60,508 | Feb 04, 2016, 12:04 PM | |
| OREX | Orexigen Therapeutics, Inc. | Booth Mark D | Chief Commercial Officer | Feb 26, 2015 | Sale | $3.67 | 100,000 | 367,200 | 53,810 | Mar 02, 2015, 05:34 PM | |
| OREX | Orexigen Therapeutics, Inc. | Booth Mark D | Chief Commercial Officer | May 30, 2014 | Option Exercise | $5.25 | 4,218 | 22,145 | 8,028 | Feb 05, 2015, 05:33 PM | |
| OREX | Orexigen Therapeutics, Inc. | Klassen Preston | SVP, Head Global Development | May 30, 2014 | Option Exercise | $5.25 | 1,318 | 6,920 | 2,588 | Feb 05, 2015, 05:32 PM | |
| OREX | Orexigen Therapeutics, Inc. | Klassen Preston | SVP, Head Global Development | Nov 28, 2014 | Option Exercise | $4.92 | 1,542 | 7,587 | 4,130 | Feb 05, 2015, 05:32 PM | |
| OREX | Orexigen Therapeutics, Inc. | Turner Heather D | SVP, Gen. Counsel & Secretary | Dec 02, 2014 | Sale | $3.83 | 45,286 | 173,445 | 22,643 | Dec 04, 2014, 05:05 PM | |
| OREX | Orexigen Therapeutics, Inc. | Turner Heather D | SVP, Gen. Counsel & Secretary | Nov 24, 2014 | Sale | $3.72 | 48,012 | 178,437 | 24,006 | Nov 26, 2014, 05:01 PM | |
| OREX | Orexigen Therapeutics, Inc. | Turner Heather D | SVP, Gen. Counsel & Secretary | Nov 25, 2014 | Sale | $3.83 | 14,764 | 56,546 | 7,382 | Nov 26, 2014, 05:01 PM | |
| OREX | Orexigen Therapeutics, Inc. | BOCK LOUIS C | Director | Nov 18, 2014 | Buy | $5.58 | 625 | 3,487 | 27,677 | Nov 20, 2014, 09:16 AM | |
| OREX | Orexigen Therapeutics, Inc. | BOCK LOUIS C | Director | Nov 18, 2014 | Buy | $5.58 | 700 | 3,905 | 700 | Nov 20, 2014, 09:16 AM | |
| OREX | Orexigen Therapeutics, Inc. | BOCK LOUIS C | Director | Nov 12, 2014 | Buy | $5.57 | 27,052 | 150,544 | 27,052 | Nov 13, 2014, 09:27 AM | |
| OREX | Orexigen Therapeutics, Inc. | Turner Heather D | VP, Gen. Counsel & Secretary | Sep 22, 2014 | Option Exercise | $3.06 | 600,000 | 1,837,500 | 300,000 | Sep 22, 2014, 06:49 PM | |
| OREX | Orexigen Therapeutics, Inc. | Hagan Joseph P | Sr. VP, Corporate Development | Sep 15, 2014 | Buy | $4.69 | 5,000 | 23,450 | 13,026 | Sep 15, 2014, 03:11 PM | |
| OREX | Orexigen Therapeutics, Inc. | NARACHI MICHAEL | President and CEO | Sep 15, 2014 | Buy | $4.78 | 50,000 | 239,100 | 58,026 | Sep 15, 2014, 02:41 PM | |
| OREX | Orexigen Therapeutics, Inc. | DOVEY BRIAN H | Director | Apr 22, 2014 | Option Exercise | $0.00200 | 4,613,521 | 9,229 | 7,580,065 | Apr 23, 2014, 05:15 PM | |
| OREX | Orexigen Therapeutics, Inc. | DOVEY BRIAN H | Director | Apr 22, 2014 | Option Exercise | $0.00201 | 78,835 | 158 | 129,463 | Apr 23, 2014, 05:15 PM | |
| OREX | Orexigen Therapeutics, Inc. | Turner Heather D | VP, Gen. Counsel & Secretary | Nov 29, 2013 | Option Exercise | $5.34 | 3,980 | 21,253 | 3,980 | Feb 11, 2014, 07:33 AM | |
| OREX | Orexigen Therapeutics, Inc. | Hagan Joseph P | Chief Business Officer | Nov 29, 2013 | Option Exercise | $5.34 | 3,980 | 21,253 | 3,980 | Feb 11, 2014, 07:33 AM | |
| OREX | Orexigen Therapeutics, Inc. | Klassen Preston | SVP, Head Global Development | Nov 29, 2013 | Option Exercise | $5.34 | 1,270 | 6,782 | 1,270 | Feb 11, 2014, 07:33 AM | |
| OREX | Orexigen Therapeutics, Inc. | Booth Mark D | Chief Commercial Officer | Nov 29, 2013 | Option Exercise | $5.34 | 3,810 | 20,345 | 3,810 | Feb 11, 2014, 07:32 AM | |
| OREX | Orexigen Therapeutics, Inc. | NARACHI MICHAEL | President and CEO | Nov 29, 2013 | Option Exercise | $5.34 | 3,980 | 21,253 | 3,980 | Feb 11, 2014, 07:32 AM | |
| OREX | Orexigen Therapeutics, Inc. | Hagan Joseph P | Chief Business Officer | Jul 31, 2013 | Option Exercise | $4.73 | 24,000 | 113,520 | 12,000 | Aug 02, 2013, 07:34 PM | |
| OREX | Orexigen Therapeutics, Inc. | Booth Mark D | Chief Commercial Officer | Jul 26, 2013 | Sale | $4.61 | 129,534 | 596,596 | 64,767 | Jul 29, 2013, 07:50 PM | |
| OREX | Orexigen Therapeutics, Inc. | Hagan Joseph P | Chief Business Officer | Jul 26, 2013 | Option Exercise | $4.53 | 20,000 | 90,600 | 10,000 | Jul 29, 2013, 07:49 PM | |
| OREX | Orexigen Therapeutics, Inc. | Klassen Preston | SVP, Head Global Development | Jul 25, 2013 | Option Exercise | $4.41 | 142,458 | 628,240 | 71,229 | Jul 29, 2013, 07:49 PM | |
| OREX | Orexigen Therapeutics, Inc. | Klassen Preston | SVP, Head Global Development | May 28, 2013 | Sale | $4.43 | 57,542 | 255,118 | 28,771 | May 30, 2013, 05:38 PM | |
| OREX | Orexigen Therapeutics, Inc. | Hagan Joseph P | Chief Business Officer | May 28, 2013 | Sale | $4.33 | 56,000 | 242,480 | 28,000 | May 30, 2013, 05:38 PM | |
| OREX | Orexigen Therapeutics, Inc. | Booth Mark D | Chief Commercial Officer | Mar 11, 2013 | Sale | $4.17 | 55,370 | 230,616 | 27,685 | Mar 12, 2013, 08:26 PM | |
| OREX | Orexigen Therapeutics, Inc. | Booth Mark D | Chief Commercial Officer | Jan 15, 2013 | Sale | $4.17 | 44,630 | 185,884 | 22,315 | Jan 18, 2013, 06:02 AM | |
| OREX | Orexigen Therapeutics, Inc. | NARACHI MICHAEL | President and CEO | Jul 17, 2012 | Option Exercise | $4.66 | 300,000 | 1,399,030 | 124,238 | Jul 19, 2012, 08:07 PM | |
| OREX | Orexigen Therapeutics, Inc. | Turner Heather D | SVP, Gen. Counsel & Secretary | Jul 17, 2012 | Option Exercise | $4.67 | 164,866 | 770,287 | 82,433 | Jul 19, 2012, 07:59 PM | |
| OREX | Orexigen Therapeutics, Inc. | Hagan Joseph P | Chief Business Officer | Jul 13, 2012 | Option Exercise | $4.21 | 60,000 | 252,800 | 30,000 | Jul 13, 2012, 08:13 PM | |
| OREX | Orexigen Therapeutics, Inc. | NARACHI MICHAEL | President and CEO | Jul 12, 2012 | Option Exercise | $4.16 | 5,800 | 24,128 | 2,900 | Jul 13, 2012, 08:13 PM | |
| OREX | Orexigen Therapeutics, Inc. | NARACHI MICHAEL | President and CEO | Jul 13, 2012 | Option Exercise | $4.18 | 294,200 | 1,229,756 | 147,100 | Jul 13, 2012, 08:13 PM | |
| OREX | Orexigen Therapeutics, Inc. | Hagan Joseph P | Chief Business Officer | Jun 27, 2012 | Sale | $3.46 | 140,000 | 484,200 | 70,000 | Jun 29, 2012, 06:58 PM | |
| OREX | Orexigen Therapeutics, Inc. | Hagan Joseph P | Chief Business Officer | Jun 28, 2012 | Option Exercise | $3.78 | 52,000 | 196,560 | 26,000 | Jun 29, 2012, 06:58 PM | |
| OREX | Orexigen Therapeutics, Inc. | Hagan Joseph P | Chief Business Officer | Jun 29, 2012 | Option Exercise | $3.98 | 24,000 | 95,520 | 12,000 | Jun 29, 2012, 06:58 PM | |
| OREX | Orexigen Therapeutics, Inc. | Booth Mark D | Chief Commercial Officer | Jun 28, 2012 | Option Exercise | $3.66 | 206,618 | 756,222 | 103,309 | Jun 29, 2012, 06:58 PM | |
| OREX | Orexigen Therapeutics, Inc. | NARACHI MICHAEL | President and CEO | Jun 28, 2012 | Sale | $3.66 | 200,000 | 732,000 | 100,000 | Jun 29, 2012, 06:58 PM | |
| OREX | Orexigen Therapeutics, Inc. | NARACHI MICHAEL | President and CEO | Jun 29, 2012 | Option Exercise | $3.87 | 250,000 | 967,500 | 125,000 | Jun 29, 2012, 06:58 PM | |
| OREX | Orexigen Therapeutics, Inc. | TURNER DANIEL K III | Director | Dec 22, 2011 | Buy | $1.45 | 57,204 | 82,946 | 377,958 | Feb 06, 2012, 08:25 PM | |
| OREX | Orexigen Therapeutics, Inc. | DP VII ASSOCIATES LP | 10% Owner | Dec 22, 2011 | Buy | $1.45 | 7,882 | 11,429 | 50,643 | Dec 22, 2011, 05:51 PM | |
| OREX | Orexigen Therapeutics, Inc. | DOMAIN PARTERS VII L P | 10% Owner | Dec 22, 2011 | Buy | $1.45 | 461,265 | 668,834 | 2,967,415 | Dec 22, 2011, 05:48 PM | |
| OREX | Orexigen Therapeutics, Inc. | BLAIR JAMES C | 10% Owner | Dec 22, 2011 | Buy | $1.45 | 461,265 | 668,834 | 2,967,415 | Dec 22, 2011, 05:43 PM | |
| OREX | Orexigen Therapeutics, Inc. | BLAIR JAMES C | 10% Owner | Dec 22, 2011 | Buy | $1.45 | 7,882 | 11,429 | 50,643 | Dec 22, 2011, 05:43 PM | |
| OREX | Orexigen Therapeutics, Inc. | VITULLO NICOLE | 10% Owner | Dec 22, 2011 | Buy | $1.45 | 461,265 | 668,834 | 2,967,415 | Dec 22, 2011, 05:40 PM | |
| OREX | Orexigen Therapeutics, Inc. | VITULLO NICOLE | 10% Owner | Dec 22, 2011 | Buy | $1.45 | 7,882 | 11,429 | 50,643 | Dec 22, 2011, 05:40 PM | |
| OREX | Orexigen Therapeutics, Inc. | SCHOEMAKER KATHLEEN K | 10% Owner | Dec 22, 2011 | Buy | $1.45 | 7,882 | 11,429 | 50,643 | Dec 22, 2011, 05:37 PM | |
| OREX | Orexigen Therapeutics, Inc. | SCHOEMAKER KATHLEEN K | 10% Owner | Dec 22, 2011 | Buy | $1.45 | 461,265 | 668,834 | 2,967,415 | Dec 22, 2011, 05:37 PM | |
| OREX | Orexigen Therapeutics, Inc. | TREU JESSE I | 10% Owner | Dec 22, 2011 | Buy | $1.45 | 461,265 | 668,834 | 2,967,415 | Dec 22, 2011, 05:33 PM | |
| OREX | Orexigen Therapeutics, Inc. | TREU JESSE I | 10% Owner | Dec 22, 2011 | Buy | $1.45 | 7,882 | 11,429 | 50,643 | Dec 22, 2011, 05:33 PM | |
| OREX | Orexigen Therapeutics, Inc. | Halak Brian K | 10% Owner | Dec 22, 2011 | Buy | $1.45 | 461,265 | 668,834 | 2,967,415 | Dec 22, 2011, 05:28 PM | |
| OREX | Orexigen Therapeutics, Inc. | Halak Brian K | 10% Owner | Dec 22, 2011 | Buy | $1.45 | 7,882 | 11,429 | 50,643 | Dec 22, 2011, 05:28 PM | |
| OREX | Orexigen Therapeutics, Inc. | DOVEY BRIAN H | Director | Dec 22, 2011 | Buy | $1.45 | 461,265 | 668,834 | 2,967,415 | Dec 22, 2011, 05:13 PM | |
| OREX | Orexigen Therapeutics, Inc. | DOVEY BRIAN H | Director | Dec 22, 2011 | Buy | $1.45 | 7,882 | 11,429 | 50,643 | Dec 22, 2011, 05:13 PM | |
| OREX | Orexigen Therapeutics, Inc. | POWELL MICHAEL | Director | Dec 21, 2010 | Sale | $8.38 | 375,339 | 3,145,116 | 371,184 | Dec 23, 2010, 06:18 PM | |
| OREX | Orexigen Therapeutics, Inc. | POWELL MICHAEL | Director | Dec 22, 2010 | Sale | $8.30 | 250,721 | 2,081,661 | 164,289 | Dec 23, 2010, 06:18 PM | |
| OREX | Orexigen Therapeutics, Inc. | POWELL MICHAEL | Director | Dec 23, 2010 | Sale | $8.09 | 198,940 | 1,609,504 | 0 | Dec 23, 2010, 06:18 PM | |
| OREX | Orexigen Therapeutics, Inc. | TURNER DANIEL K III | Director | Dec 22, 2010 | Sale | $8.25 | 51,943 | 428,530 | 546,769 | Dec 23, 2010, 04:46 PM | |
| OREX | Orexigen Therapeutics, Inc. | POWELL MICHAEL | Director | Dec 17, 2010 | Sale | $8.76 | 131,254 | 1,149,575 | 949,104 | Dec 21, 2010, 05:34 PM | |
| OREX | Orexigen Therapeutics, Inc. | POWELL MICHAEL | Director | Dec 20, 2010 | Sale | $8.50 | 325,000 | 2,763,995 | 680,914 | Dec 21, 2010, 05:34 PM | |
| OREX | Orexigen Therapeutics, Inc. | SENATOR RON | member of 10% owner group | Jul 12, 2010 | Sale | $4.15 | 20,000 | 82,990 | 571,877 | Aug 16, 2010, 06:47 AM | |
| OREX | Orexigen Therapeutics, Inc. | M. ARKIN (1999) LTD. | member of 10% owner group | Jul 12, 2010 | Sale | $4.15 | 20,000 | 82,990 | 571,877 | Aug 16, 2010, 06:12 AM | |
| OREX | Orexigen Therapeutics, Inc. | M. ARKIN (1999) LTD. | member of 10% owner group | Jul 15, 2010 | Sale | $5.64 | 105,000 | 591,685 | 4,037,766 | Aug 16, 2010, 06:12 AM | |
| OREX | Orexigen Therapeutics, Inc. | M. ARKIN (1999) LTD. | member of 10% owner group | Jul 12, 2010 | Sale | $4.15 | 135,000 | 560,182 | 4,142,766 | Aug 16, 2010, 06:12 AM |
Menu